Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Zhujiang Hospital is the lead sponsor of 55 current clinical trials in our China register. 41 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Axicabtagene Ciloleucel, Azacitidine and Chidamide. The most-studied condition is Multiple Myeloma.

ClinicalTrials.gov trials by status

Recruiting4175%
Not yet open1018%
Active, closed12%
By invitation35%

Trials by phase

Observational3156%
Not applicable815%
Phase 1/2611%
Phase 247%
Phase 424%
Phase EARLY_PHASE124%
Phase 2/312%
Phase 112%

Clinical trials sponsored by Zhujiang Hospital

55 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU) NCT07469072 · ClinicalTrials.gov ↗ · Continuous Renal Replacement Therapy (CRRT)	Phase 2	Recruiting	2026-04	China
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer NCT07534033 · ClinicalTrials.gov ↗ · NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection	Phase 2	Recruiting	2025-12	China
A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke NCT06712004 · ClinicalTrials.gov ↗ · Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction	Phase 2	Recruiting	2025-02	China
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse NCT05270200 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute Drugs: Azacitidine, Chidamide	Phase 1/2	Recruiting	2022-02	China
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma NCT06902012 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-cell Lymphoma Drug: Axicabtagene Ciloleucel	Phase 1/2	Recruiting	2027-02	China
Validation of the Accuracy of a Novel POCT Dry Electrolyte Analysis System in the Acute Care Setting NCT06726460 · ClinicalTrials.gov ↗ · Electrolyte Disorder, Arrhythmia, Stroke	Observational	Recruiting	2024-12	China
A Study on the Correlation Between Endometriosis and Intra-tissue Microbiota NCT06266897 · ClinicalTrials.gov ↗ · Endometriosis	Observational	Recruiting	2023-06	China
Objective Response Rate of Ivonescimab With Chemotherapy in Locally Advanced Resectable Oral and Oropharyngeal Squamous Cell Carcinoma NCT07686575 · ClinicalTrials.gov ↗ · HNSCC, OSCC, OPSCC	Observational	Recruiting	2026-01	China
Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy NCT07111455 · ClinicalTrials.gov ↗ · Locally Advanced Oral Squamous Cell Carcinoma	Observational	Recruiting	2025-07	China
Effect of Remimazolam With Protocolized Sedation on Critical Ill, Mechanical Ventilated Patients Compared With Midazolam NCT05160987 · ClinicalTrials.gov ↗ · Sedation and Analgesia Drugs: Midazolam, Remimazolam	Not applicable	Recruiting	2022-03	China
The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System. NCT07330362 · ClinicalTrials.gov ↗ · Chronic Glomerulonephritis, Chronic Kidney Disease	Observational	Recruiting	2024-07	China
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD NCT06449833 · ClinicalTrials.gov ↗ · Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease	Phase 4	Recruiting	2024-06	China
Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer NCT05067101 · ClinicalTrials.gov ↗ · Bladder Cancer	Not applicable	Recruiting	2024-09	China
Effectiveness of tTIs for Improving Consciousness in Patients With DoC NCT07539740 · ClinicalTrials.gov ↗ · Disorders of Consciousness, Vegetative State, Minimally Conscious State	Not applicable	Recruiting	2026-03	China
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study NCT07072494 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 1/2	Recruiting	2025-07	China
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy NCT06690593 · ClinicalTrials.gov ↗ · Monoclonal Gammopathy of Undetermined Significance (MGUS), Intestinal Flora, Multiple Myeloma	Observational	Recruiting	2024-12	China
Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP NCT07380113 · ClinicalTrials.gov ↗ · Pruritus Chronic, Kidney Diseases, Chronic, Renal Insufficiency, Chronic	Phase 4	Recruiting	2026-06	China
A Multicenter Cohort Study on Maternal and Infant Microecology and New Targets for Pre-eclampsia Screening in China NCT05445544 · ClinicalTrials.gov ↗ · Preeclampsia, Microbiome	Observational	Recruiting	2022-10	China
Pipeline Embolization for Intracranial Aneurysms NCT06446778 · ClinicalTrials.gov ↗ · Efficacy, Self, Hemodynamic Instability, Stenosis	Observational	Recruiting	2022-09	China
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA NCT06157060 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Resectable	Observational	Recruiting	2023-11	China
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence NCT06644937 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2/3	Recruiting	2024-11	China
The Correlation of Intracranial Artery Calcification and Outcomes of Mechanical Thrombectomy NCT06418698 · ClinicalTrials.gov ↗ · Stroke, Acute, Ischemic Stroke, Vascular Diseases	Observational	Recruiting	2024-03	China
Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study NCT06861114 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Observational	Recruiting	2025-02	China
Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform. NCT06097065 · ClinicalTrials.gov ↗ · Prediabetes, Diabetes Mellitus, Gestational Diabetes Mellitus	Observational	Recruiting	2022-05	China
Observation on the Correlation Between Serum/Fecal Isoflavones, Abundance of TMA-producing Bacteria and Serum TMAO in Hyperlipidemia and Healthy Subjects NCT06890780 · ClinicalTrials.gov ↗ · Hyperlipidemia	Observational	Recruiting	2023-01	China
Risk Assessment and Mechanism Analysis of Intracranial Multiple Aneurysm Instability Based on High-resolution Magnetic Resonance, Imaging Histology and Hemodynamics NCT06539767 · ClinicalTrials.gov ↗ · Arterial Aneurysm Wall Enhancement on HRMRI	Observational	Recruiting	2023-01	China
Omics Sequencing of Specimen Derived From Mother-Infant-Pairs NCT05462366 · ClinicalTrials.gov ↗ · Healthy, Breast-milk Collection, Feces	Observational	Recruiting	2021-06	China
Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Patients With Disorders of Consciousness NCT07284732 · ClinicalTrials.gov ↗ · Disorders of Consciousness	Not applicable	Recruiting	2024-05	China
A Bidirectional Observational Clinical Study of NAIC in the Treatment of Tumor Regression Patterns in LA-OSCC and LA-OPSCC NCT07133958 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC)	Observational	Recruiting	2023-07	China
Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects NCT04861584 · ClinicalTrials.gov ↗ · Urinary Bladder Cancer Drugs: Gemcitabine and cisplatin, Neoadjuvant toripalimab	Phase 2	Recruiting	2021-06	China
Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis NCT05686447 · ClinicalTrials.gov ↗ · Monoclonal Gammopathies, Multiple Myeloma, M-protein	Observational	Recruiting	2023-01	China
A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial NCT06215495 · ClinicalTrials.gov ↗ · Radiation Toxicity, MRI Simulated Positioning, High Grade Glioma	Not applicable	Recruiting	2024-02	China
RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients NCT06341400 · ClinicalTrials.gov ↗ · Bladder Cancer, Muscle-Invasive Bladder Carcinoma	Phase 1/2	Recruiting	2024-06	China
The Supraspinal Control of Lower Urinary Tract Function in Patients with Orthotopic Sigmoid Neobladder. NCT05558111 · ClinicalTrials.gov ↗ · Orthotopic Neobladder	Observational	Recruiting	2022-06	China
Hemodynamic Study of In-Stent Stenosis(I) After Flow Diverter(F) Based on 3D-DSA(D) Combined With TCCD(T) NCT06448949 · ClinicalTrials.gov ↗ · Hemodynamics;In-stent Stenosis;Transcranial Doppler;Intracranial Aneurysm;Flow Diverter; Prospective Cohort Study	Observational	Recruiting	2024-06	China
Detection of Sepsis Occurrence by Using Blood Fluorescence NCT06745115 · ClinicalTrials.gov ↗ · Sepsis	Observational	Recruiting	2023-09	China
Epidemiological Insights Into the Formation, Progression, and Rupture of Intracranial Aneurysms: A Retrospective, Multi-Center Hospital-Based Study in China NCT06456814 · ClinicalTrials.gov ↗ · Intracranial Aneurysm, Subarachnoid Hemorrhage, Aneurysmal, Cerebral Aneurysm	Observational	Recruiting	2010-01	China
Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) NCT07362095 · ClinicalTrials.gov ↗ · Acute Leukemia Drug: Luspatercept	Phase 1/2	Recruiting	2025-10	China
A Study on the Correlation Between Cotinine Levels and Aneurysm Wall Enhancement on HRMRI. NCT06447714 · ClinicalTrials.gov ↗ · Cotinine Levels, Arterial Aneurysm Wall Enhancement on HRMRI	Observational	Recruiting	2022-09	China
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients NCT06539832 · ClinicalTrials.gov ↗ · Multiple Myeloma, MGUS, Gut Microbiota	Observational	Recruiting	2024-05	China
A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method. NCT06082284 · ClinicalTrials.gov ↗ · Multiple Myeloma, M Protein	Observational	Recruiting	2023-10	China
Effect of Vegan Diet on Microbiome and Metabolism NCT07003230 · ClinicalTrials.gov ↗ · Vegan Diet	Not applicable	Not yet open	2025-05	China
Plasma Neprilysin for Predicting Sepsis Within 48 Hours in ICU Patients With Infection or Suspected Infection NCT07796386 · ClinicalTrials.gov ↗ · Sepsis, Infection	Observational	Not yet open	2026-08	China
An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines With Metabolic Dysfunction-associated Fatty Liver Disease NCT07455149 · ClinicalTrials.gov ↗ · Metabolic Dysfunction-associated Fatty Liver Disease	Observational	Not yet open	2026-04	China
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma NCT06449846 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Resectable, Surgery, Recurrence	Observational	Not yet open	2024-06	China
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS NCT06317896 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence	Observational	Not yet open	2024-04	China
Observational Clinical Study on the Association Between Lactate-mediated Gut Microbiota Alterations and Disease Progression in Liver Cirrhosis. NCT07455175 · ClinicalTrials.gov ↗ · Cirrhosis	Observational	Not yet open	2026-04	China
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia NCT07696481 · ClinicalTrials.gov ↗ · Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Acute Myeloid Leukemia (AML)	Phase EARLY_PHASE1	Not yet open	2026-08	China
The Correlation Characteristics Between Mental Health and Gut Microbiota of College Students in Qingyuan Vocational Education City NCT06595095 · ClinicalTrials.gov ↗ · Depression, Anxiety	Observational	Not yet open	2024-10	China
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma NCT07457099 · ClinicalTrials.gov ↗ · Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma	Observational	Not yet open	2026-04	China
Exploratory Study of Intranasal Administration of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Ischemic Stroke NCT07232563 · ClinicalTrials.gov ↗ · Ischemic Stroke	Phase 1	Not yet open	2025-12	China
The Construction and Effect Verification of a Deep Learning-based Automated Semantic Segmentation Model for Medical Imaging NCT06864702 · ClinicalTrials.gov ↗ · Artificial Intelligence (AI), Deep Learning, Laparoscopic Surgery	Not applicable	By invitation	2023-12	China
Racecadotril for Organ Injury in Sepsis Patients NCT07454421 · ClinicalTrials.gov ↗ · Sepsis	Phase 1/2	By invitation	2026-05	China
Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer NCT07112209 · ClinicalTrials.gov ↗ · Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer	Not applicable	By invitation	2023-11	China
Effects of DL-endopeptidase Producing Probiotics on Human Intestinal NOD2 Ligands and Related Functions NCT06716047 · ClinicalTrials.gov ↗ · Microecological Therapy, Probiotic Intervention	Phase EARLY_PHASE1	Active, closed	2024-12	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Zhujiang Hospital trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Axicabtagene Ciloleucel1 Azacitidine1 Chidamide1 Gemcitabine and cisplatin1 Luspatercept1 Midazolam1 Neoadjuvant toripalimab1 Remimazolam1

Conditions in Zhujiang Hospital trials

101 conditions

Multiple Myeloma4 Sepsis3 Ischemic Stroke3Locally Advanced Oral Squamous Cell Carcinoma2Bladder Cancer2Disorders of Consciousness2Hepatocellular Carcinoma Resectable2Surgery2Recurrence2Hepatocellular Carcinoma (HCC)2Arterial Aneurysm Wall Enhancement on HRMRI2Continuous Renal Replacement Therapy (CRRT)1Vegan Diet1Infection1NSCLC Diagnosed by Histology or Cytology1A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection1Overall Lung Function is Adequate for the Planned Lung Resection1AJCC is Classified as IB-IIIC1Ischemic Stroke, Acute1 Cerebral Infarction1 Brain Diseases1 Leukemia, Myeloid, Acute1Relapsed/Refractory Diffuse Large B-cell Lymphoma1Electrolyte Disorder1

By trial register

Register	Trials	Recruiting
Clinical trials in China	55	41

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Multiple Myeloma

Sponsor	Trials
Janssen Research & Development	24
AbbVie	13
GlaxoSmithKline	13
Pfizer	8
Celgene	5
Regeneron Pharmaceuticals	3
European Myeloma Network	3
Nanjing IASO Biotechnology	3
Genrix (Shanghai) Biopharmaceutical	3
Xuzhou Medical University	3

Sponsors with the most current trials registered for this condition.

Questions about Zhujiang Hospital trials

How many clinical trials does Zhujiang Hospital sponsor?

Zhujiang Hospital is the lead sponsor of 55 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Zhujiang Hospital trials recruiting?

Yes. 41 of its 55 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Zhujiang Hospital testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are Axicabtagene Ciloleucel (1), Azacitidine (1), Chidamide (1), Gemcitabine and cisplatin (1) and Luspatercept (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Zhujiang Hospital clinical trials